CT18 Infant Influenza Priming Study in Vaccine Naive Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

July 21, 2021

Study Completion Date

July 21, 2021

Conditions
Influenza
Interventions
BIOLOGICAL

aTIV Primer

MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart

BIOLOGICAL

QIV Primer

Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart

BIOLOGICAL

aTIV Booster

MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2

BIOLOGICAL

QIV Booster

Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2

Trial Locations (4)

V5Z 4H4

Vaccine Evaluation Center, BC Children's Hospital, Vancouver

B3K 6R8

IWK Health Centre, Halifax

H9H 4Y6

Research Institute of the McGill University health Centre, Montreal

G1E 7G9

Équipe de recherche en vaccination CHU de Québec-Université Laval, Québec

All Listed Sponsors
collaborator

Provincial Health Services Authority

OTHER

collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

collaborator

Université de Montréal

OTHER

collaborator

Canadian Center for Vaccinology

OTHER

collaborator

CHU de Quebec-Universite Laval

OTHER

collaborator

Dalhousie University

OTHER

lead

Canadian Immunization Research Network

NETWORK

NCT03669627 - CT18 Infant Influenza Priming Study in Vaccine Naive Infants | Biotech Hunter | Biotech Hunter